The University of Chicago Header Logo

Connection

Randy Sweis to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications Randy Sweis has written about Antineoplastic Agents.
Randy Sweis
Connection Strength
0.092
Antineoplastic Agents
  1. Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 05 13; 28(10):2020-2029.
    View in: PubMed
    Score: 0.092
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.